feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Region
Access
  • 1
    UID:
    b3kat_BV048984103
    Format: 1 Online-Ressource (VI, 356 Seiten) , Illustrationen, Pläne
    ISBN: 9783161589157
    Series Statement: Otium 13
    Note: Enthält Beiträge des interdisziplinären Workshops "Das Bad als Mußeraum", der am 30. und 31. Oktober 2015 am Freiburg Institute for Advanced Studies (FRIAS) stattfand
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-16-158914-0
    Language: German
    Subjects: History , Ethnology
    RVK:
    RVK:
    RVK:
    RVK:
    RVK:
    Keywords: Bad ; Kultur ; Muße ; Geschichte ; Bad ; Architektur ; Geschichte ; Konferenzschrift ; Konferenzschrift
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    Author information: Hubert, Hans W. 1960-
    Author information: Grebe, Anja 1968-
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    UID:
    almahu_9949435851002882
    Format: 1 online resource (252 pages)
    ISBN: 0-12-822711-7
    Content: Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their participation to immunotherapy management. The book provides updated information on the main applications of liquid biopsy and immunotherapy as well as interesting aspects useful for planning basic and translational research activities. It helps readers understand the central aspects of precision medicine in oncology, including the use of new generation technologies for translational and diagnostic settings and the main clinical trials in this area that may be useful during their research.
    Note: Front Cover -- Liquid Biopsy -- Copyright Page -- Contents -- List of contributors -- Preface -- 1 What is precision medicine in oncology? -- 1.1 Introduction: what does precision medicine mean? -- 1.2 The role of biomarkers in precision medicine -- 1.3 Classification of biomarkers -- 1.4 The rationale for the definition of tumor mutational burden -- 1.5 Collecting samples for mutational analysis: tissue or liquid biopsy? -- 1.6 Pragmatical aspects of precision medicine: how to build it? -- 1.7 Precision medicine and clinical trials: is there something different? -- 1.8 Precision medicine in oncology: what is its "area-of-application"? -- 1.9 Pharmacogenomics and precision medicine -- 1.10 Determination of programmed death-ligand 1 expression in non-small cell lung carcinoma in order to choose patients eli... -- 1.11 Through the concept of synthetic lethality: poly ADP-ribose polymerases-inhibitors and precision medicine -- 1.12 Colorectal cancer e microsatellite instability -- 1.13 Conclusions -- Conflict of interest statement -- References -- 2 Liquid biopsy: a right tool in a right context? -- Subchapter 2.1 Liquid biopsy in NSCLC -- Learning objectives -- 2.1.1 Expert opinion -- 2.1.2 Key points -- 2.1.3 Summary of clinical recommendations -- Acknowledgments -- References -- Further reading -- Subchapter 2.2 The role of mutated ctDNA in nonmalignant lesions: challenging aspects in liquid biopsy implementation -- Learning objectives -- 2.2.1 Expert opinion -- 2.2.2 Key points -- Acknowledgments -- References -- Further reading -- 3 Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology -- Learning objectives -- 3.1 Tissue or liquid biopsy? -- 3.2 Next-generation sequencing for identification of gene alterations in liquid biopsy. , 3.3 Liquid biopsy in monitoring response to therapy -- 3.4 Expert opinion -- 3.5 Key points -- 3.6 Hints for deeper insight -- References -- Further reading -- 4 Current clinically validated applications of liquid biopsy -- Learning objectives -- 4.1 Circulating tumor DNA in advanced non-small cell lung cancer -- 4.1.1 Treatment-naïve advanced non-small cell lung cancer patients -- 4.1.2 Advanced non-small cell lung cancer patients progressing during tyrosine kinase inhibitors -- 4.2 Emerging clinical applications of liquid biopsy -- 4.2.1 Colorectal cancer -- 4.2.2 Breast cancer -- 4.2.3 Melanoma -- 4.3 Liquid biopsy application in clinical research -- 4.3.1 Monitoring of treatment response in lung cancer -- 4.3.2 Monitoring of treatment response in colorectal cancer -- 4.4 Key points -- Acknowledgments -- References -- 5 Liquid biopsy and immunotherapy: is all that glitter gold? -- Learning objectives -- 5.1 Background: the need for predictive biomarkers for patient selection -- 5.1.1 Circulating tumor cells, cell-free DNA, and exosomes -- 5.1.2 Circulating tumor cells -- 5.1.3 Cell-free DNA and circulating tumor DNA -- 5.1.4 Exosomes -- 5.1.5 T-lymphocytes (the T-cell receptor) and cytokines -- 5.1.6 The soluble form of immune-checkpoints and other circulating proteins -- Abbreviations -- Key points -- Expert opinion -- Acknowledgments -- References -- 6 Which technology performs better? From sample volume to extraction and molecular profiling -- Subchapter 6.1 Molecular profiling -- Learning objectives -- 6.1.1 Expert opinion -- 6.1.2 Key points -- References -- Further reading -- Subchapter 6.2 Biological fluid withdrawal: how much sample volume is enough? -- Learning objectives -- 6.2.1 Introduction -- 6.2.2 Other body fluids used in liquid biopsy-based assays -- 6.2.3 Key points -- References -- Further reading. , Subchapter 6.3 Methods for cf/ct DNA isolation -- Learning objectives -- 6.3.1 Key points -- Acknowledgments -- References -- Further reading -- Subchapter 6.4 CTC and exosome: from the enrichment to the characterization -- Learning objectives -- 6.4.1 Introduction -- 6.4.2 Exosome enrichment -- 6.4.3 Exosomes characterization -- 6.4.3.1 Role of exosomes in immunotherapy -- 6.4.4 Circulating tumor cells enrichment methods -- 6.4.4.1 Role of circulating tumor cells in immunotherapy -- 6.4.5 Key points -- References -- Further reading -- Subchapter 6.5 Circulating RNAs (miRNA, lncRNA, etc): from the enrichment to the characterization -- Learning objectives -- 6.5.1 Introduction -- 6.5.2 Housekeeping RNAs -- 6.5.3 Regulatory ncRNAs -- 6.5.4 Key points -- 6.5.5 Expert opinion -- Acknowledgments -- References -- Further reading -- Subchapter 6.6 Cell-free/circulating tumor DNA profiling: from next-generation sequencing-based to digital polymerase chain... -- Learning objectives -- 6.6.1 Introduction -- 6.6.2 Targeted next-generation sequencing methods -- 6.6.3 Untargeted next-generation sequencing methods -- 6.6.4 Droplet digital polymerase chain reaction methods -- 6.6.5 Key points -- 6.6.6 Expert opinion -- Acknowledgments -- References -- Subchapter 6.7 Standardization and quality assurance in liquid biopsy testing -- Learning objectives -- 6.7.1 Introduction -- 6.7.2 Cell-free DNA in liquid biopsy: preanalytical limitations -- 6.7.3 The preanalytical phase of circulating tumor cells analysis -- 6.7.4 The preanalytical phase of exosomes analysis -- 6.7.4.1 Sample collection, storage, and processing -- 6.7.4.2 Exosomes isolation -- 6.7.4.2.1 Ultracentrifugation-based isolation techniques -- 6.7.4.2.2 Ultrafiltration and size exclusion chromatography -- 6.7.4.2.3 Polymer precipitation -- 6.7.4.2.4 Immunoaffinity methods. , 6.7.4.2.5 Microfluidics-based methods -- 6.7.5 Standardization initiatives and ISO/CEN/external quality assessment development in liquid biopsy -- 6.7.6 Key points -- 6.7.7 Expert opinion -- Acknowledgments -- References -- Further reading -- 7 Early detection screening: myth or reality? -- References -- 8 Molecular tumor board -- Learning objectives -- Expert opinion -- Key points -- Acknowledgments -- References -- 9 Future perspectives -- Acknowledgments -- References -- Glossary -- Index -- Back Cover.
    Additional Edition: Print version: Russo, Antonio Liquid Biopsy San Diego : Elsevier Science & Technology,c2022 ISBN 9780128227039
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    UID:
    almahu_9949357437602882
    Format: XIV, 122 p. 21 illus., 18 illus. in color. , online resource.
    Edition: 1st ed. 2022.
    ISBN: 9783030977443
    Series Statement: Current Clinical Pathology,
    Content: The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.
    Note: 1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.
    In: Springer Nature eBook
    Additional Edition: Printed edition: ISBN 9783030977436
    Additional Edition: Printed edition: ISBN 9783030977450
    Additional Edition: Printed edition: ISBN 9783030977467
    Language: English
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    UID:
    almafu_BV026093090
    Format: 433 S.
    ISBN: 88-382-3616-X
    Series Statement: La cultura 40
    Note: Zugl.: Tübingen, Univ., Diss., 1989
    Subjects: Theology
    RVK:
    Keywords: 1896-1991 Lubac, Henri de ; Theologie ; 1861-1949 Blondel, Maurice ; 1896-1991 Lubac, Henri de ; Hochschulschrift ; Hochschulschrift ; Hochschulschrift
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Cham :Springer International Publishing, | Cham :Springer.
    UID:
    almafu_BV047580770
    Format: 1 Online-Ressource (XXIV, 1112 p. 488 illus., 429 illus. in color).
    Edition: 1st ed. 2021
    ISBN: 978-3-030-56051-5
    Series Statement: UNIPA Springer Series
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-56050-8
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-56052-2
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-56053-9
    Language: English
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    UID:
    edoccha_BV048885951
    Format: 1 Online-Ressource (VII, 117 p. 4 illus., 1 illus. in color).
    ISBN: 978-3-031-24060-7
    Series Statement: UNIPA Springer Series
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-24059-1
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-24061-4
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-24062-1
    Language: English
    Subjects: Medicine
    RVK:
    RVK:
    Keywords: Medizinische Ethik ; Forschung ; Wissenschaftsethik ; Aufsatzsammlung
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    UID:
    gbv_168106216X
    Format: 333 Seiten , Illustrationen , 25 cm
    ISBN: 9788899618940
    Series Statement: Collana arti
    Note: Vorwort: "Il presente volume raccoglie i contributi presentati in occasione del Convegno di studi Roma-Milano, architettura e città tra XVI e XVII secolo, Sapienza Università di Roma, Roma, 14 febbraio 2019" , Includes bibliographical references and indexes
    Language: Italian
    Keywords: Mailand ; Rom ; Städtebau ; Architektur ; Geschichte 1500-1700 ; Konferenzschrift
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    UID:
    almahu_BV047622418
    Format: XXXVII, 827 Seiten.
    ISBN: 88-382-3864-2
    Series Statement: La cultura 81
    Note: Bibliographie Kardinal Walter Kasper, Seite 783-827
    Language: Italian
    Subjects: Theology
    RVK:
    RVK:
    Keywords: Festschrift ; Bildnis ; Aufsatzsammlung ; Festschrift
    Author information: Kasper, Walter, 1933-
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    UID:
    almafu_9959013987102883
    Format: 1 online resource (228 pages).
    Edition: 1st ed. 2019.
    ISBN: 3-319-93402-3
    Series Statement: Current Clinical Pathology,
    Content: This book is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about cardiovascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments, the survival of cancer patients is increasing at an exponential rate. However, the burden of related cardiovascular complications that affect morbidity and mortality are also on the rise. A new branch of cardiology, Cardio-Oncology, was developed to combat this trend. The aim of its conception is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. The text focuses on cardiovascular complications related to cancer treatment and reviews the pathophysiological mechanisms leading to cardiovascular toxicity related to various antineoplastic drugs. Diagnostic modalities for early diagnosis are also discussed, followed by preventive and therapeutic strategies. Cardiovascular Complications in Cancer Therapy serves as a valuable resource for residents, fellow physicians, medical oncologists, cardiologists, and general practitioners and all those who take care of these patients.
    Note: Introduction -- Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy -- Molecular Mechanisms of Cardiovascular Damage Induced by Anti HER2 Therapies -- Cardiovascular Damage Induced by Radiotherapy -- Cardiovascular Damage Induced by Anti-VEGF Therapy -- Cardiovascular Damage Induced by Anti-BCR-ABL TKIs -- Heart Failure and Left Ventricular Dysfunction -- Coronary Artery Disease -- Peripheral Artery Disease and Stroke -- Valvular Heart Disease -- Arterial Hypertension -- Atrial Fibrillation in Cancer -- Management of QT Prolongation Induced by Anti-cancer Drugs -- Pulmonary Hypertension Induced by Anti-cancer Drugs -- Venous Thromboembolism -- Early Detection of Cardiac Damage -- Diagnosis of Cardiac Damage: Role of Stress Echo -- Early Detection and Monitoring of Vascular Damage -- Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculo-Protection in Personalized Therapy -- Cardiovascular Damage in Clinical Trials.
    Additional Edition: ISBN 3-319-93401-5
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    UID:
    b3kat_BV047934132
    Format: 1 Online-Ressource (32 Seiten)
    Series Statement: OECD Environment Working Papers
    Content: Parking policies have significant environmental and economic implications, which have often been left unconsidered. This paper reviews the relevant literature to provide a deeper understanding of the main environmental and economic consequences of common parking policies, and suggest policy options to protect the environment and increase social welfare
    Language: English
    URL: Volltext  (URL des Erstveröffentlichers)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages